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LEUKOCYTE TELOMERE LENGTH AND ACCELERATED AGING AS 
PREDICTORS FOR THE ONSET OF PSYCHOSIS 
 
FELIX AMIRFATHI 
ABSTRACT 
Leukocyte telomere length is an emerging marker for pathologically accelerated cellular 
aging. First discovered to be associated with aging-related disorders, such as type 2 
diabetes mellitus and cardiovascular disease, in young individuals, leukocyte telomeric 
degeneration is also garnering growing attention in psychiatric illnesses. Comorbid 
metabolic symptoms and physiological dysregulation observed in schizophrenia patients 
imply a plausible association between pathological telomere biology and psychosis. 
Available data on the relationship between leukocyte telomere length and schizophrenia 
is limited largely to small-sample, cross-sectional studies unable to fully account for the 
large body of potentially confounding factors on telomere length (psychotropic 
medication, chronic stress and history of trauma, comorbidities, paternal age, substance 
use, subject-level variables). The most comprehensive meta-analysis to date reveals a 
significant trend of shortened telomeres in schizophrenia patients as compared to healthy 
controls. Some findings suggest a linear relationship between telomeric attrition and 
disease chronicity/severity. However, overall findings are insufficient to gauge the 
potential of leukocyte telomere length as a predictive, diagnostic biomarker in this patient 
population. Future longitudinal studies with carefully controlled covariates are required 
to verify the promising potential of a new marker for schizophrenia onset and a possible 
new direction for adjunctive antipsychotic treatment.                
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INTRODUCTION 
Schizophrenia is an enigmatic disorder that affects 1% of the population and for which no 
discrete biological etiology has been discovered.1 The diagnosis is based on positive 
symptoms (delusions, hallucinations, persecutory ideation), negative symptoms (social 
withdrawal, affective flattening, impaired motivation), as well as cognitive deficits. 
Though early detection is crucial in the treatment of psychotic disorders, the 
identification of individuals at risk is complicated by a wide array of associated genetic 
and environmental factors.2 Despite continued disagreements in the field surrounding the 
causality and significance of various potential biomarkers for psychosis, studies began 
identifying prominent neurodevelopmental and neurodegenerative aspects of 
schizophrenia as early as two decades ago.3,4 There continues to be support for two 
opposing models regarding whether psychotic disorders are the result of an initial 
neurodevelopmental insult or progressively worsen throughout a patient’s lifetime. 
Certain sources are arguing, however, that the two concepts are not mutually exclusive, 
and that schizophrenia should be viewed as a progressive neurodevelopmental disorder.4 
Through an upsurge in longitudinal cohort studies, advanced brain imaging techniques, 
and genetic analyses, new evidence of such progressive neurodevelopmental traits in 
schizophrenia patients has been reported in recent years.5  
 
In combination with the similarly growing body of evidence in support of accelerated 
aging in patients with psychotic disorders6, these findings of neurodegenerative 
pathophysiology suggest a plausible association between schizophrenia and heightened 
		
 
2 
telomeric shortening. Telomeres can be defined as DNA repeat structures on the ends of 
chromosomes that regulate cellular replication and protect against loss of genetic 
information.7 The inability of DNA polymerase to fully replicate the 3’ end of a given 
strand of DNA causes telomeres to shorten by a substantial number of base pairs with 
every cell division.7,8 In most eukaryotic cells, once telomeres attain a critically short 
length, the body induces cellular senescence or apoptosis. Cell types that continuously 
replicate throughout the lifespan contain the enzyme telomerase, which replenishes lost 
DNA base pairs not replicated by DNA polymerase. [Figure 1] Even though peripheral 
Figure 1 – Telomeres and Telomerase 
In humans, telomeres are comprised of repeating, noncoding TTAGGG sequences and 
are about 10,000 nucleotides long. Unless acted upon by telomerase, they lose roughly 
50-100 nucleotides per DNA replication cycle. Telomerase is comprised of a 
telomerase reverse transcriptase (TERT) and a telomerase RNA component (TERC).9 
 
Figure adapted from Lindqvist et al. (2015) 
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blood mononuclear cells (PBMCs) are among these cell types, leukocyte telomere length 
(LTL) consistently shortens by about 32.2-45.5 base pairs per year according to several 
longitudinal studies.9 LTL is therefore being considered an emerging marker for cellular 
aging.9,10 Despite being a peripheral marker, it is plausible that LTL is correlated with 
telomere length (TL) in certain brain tissues.9 However, data on concrete correlations of 
LTL to brain tissue TL, brain structural volume, or brain tissue telomerase activity are 
still largely inconclusive.9,11 Further investigations will need to be conducted in order to 
determine how accelerated leukocyte telomere degeneration is related to brain tissue. 
Acknowledging that LTL does not equate to mean brain tissue TL, the remainder of this 
thesis will not focus on studies of TL in various brain regions and will instead discuss the 
more readily measured peripheral blood cell TL as an indicator for cellular aging and 
accompanying pathologies. 
 
Possible Mechanisms of Telomere Shortening 
a) Inherited Telomerase Deficiencies 
Continued cell division in the absence of telomerase activity is possibly the most intuitive 
potential cause of pathological leukocyte telomere degeneration in psychiatric illnesses. 
Inherited telomerase deficiencies have therefore been found to be a major cause of 
shorter leukocyte telomeres.9 For instance, an autosomal dominant mutation in hTERC, 
the human telomerase RNA component, causes markedly decreased LTL and is 
associated with dyskeratosis congenita.12 Interestingly, some studies have found an 
increased incidence of neuropsychiatric conditions in patients with dyskeratosis 
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congenita.9,12 Conversely, an increased ratio of telomerase activity to LTL, especially in 
combination with lowered LTL, is indicative of cellular stress and/or failed compensatory 
attempts by telomerase to maintain LTL.9,13 While telomerase activity could be 
considered its own biomarker and is not the focus of this thesis, it is nonetheless 
intimately tied to the accelerated attrition of LTL.    
b) Inflammation 
Acute inflammation is a protective response to injury and a process that delivers 
leukocytes and antibodies to the site of infection or tissue damage.9,14 The inhibition of 
negative regulators forces this response to persist and is therefore characteristic of a 
chronic inflammatory state. In this state, leukocytes are constantly proliferating, and it is 
plausible that a rate of leukocyte proliferation greater than the rate of telomerase activity 
could be responsible for leukocyte telomere shortening. In support of this theory, a 
remarkable incidence of telomere shortening has been cited in chronic inflammatory 
disorders, a broad umbrella term encompassing chronic lung diseases, diabetes, 
autoimmune diseases, renal failure, cardiovascular disease, and chronic infections.14 
Despite this significant coincidence of LTL shortening and chronic inflammation, a 
causal relationship between LTL and inflammation has not been established. On the one 
hand, inflammation increases leukocyte proliferation thereby feasibly causing LTL 
degeneration. Alternatively, accelerated loss of telomeric sequence has been found to 
signal the production of pro-inflammatory cytokines, thereby in turn causing 
inflammation. Due to the significant coincidence of both phenomena across distinct 
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pathologies, inflammation likely both contributes to and persists as a result of telomere 
degeneration.  
c) Oxidative Stress 
Oxidative stress is a known trigger for cellular senescence. Specifically, it has been 
shown to induce DNA damage at the 5’ end of 5’-GGG-3’ telomere sequences.15 This 
suggests that oxidative stress has a causative effect on increasing the rate of telomere 
shortening. Oxidative stress may in fact play the most intrinsic role in LTL shortening, 
due to this heightened susceptibility of telomeric DNA to oxidative damage and the fact 
that the repair of oxidative damage is relatively inefficient in telomeres.9 It is well 
established that oxidative stress markers are inversely correlated with LTL in Major 
Depressive Disorder (MDD),16 suggesting that a similar association could plausibly be 
found in schizophrenia.   
 
Telomeric Degeneration in Major Psychiatric Illnesses 
An association between TL and psychiatric disorders is widely accepted in scientific 
literature. A meta-analysis published in 2016 involving 14,827 participants reported a 
robust effect size showing LTL shortening as a whole across all psychiatric disorders 
analyzed (depressive disorders, post-traumatic stress disorder, psychotic disorders, 
anxiety disorders, and bipolar disorder).10 Various studies interestingly also cite increased 
incidences of inflammation and oxidative stress in certain psychiatric illnesses.16 A 
review by Raza et al (2016), for instance, reports a strong association between oxidative 
damage to DNA and the development of psychiatric symptoms.17 Considering that 
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inflammation and oxidative stress, especially in combination,9 are underlying 
physiological mechanisms of telomeric degeneration, this reported association further 
validates the need for more exhaustive investigations into the relationship between LTL 
and psychiatric disorders.  
 
Research within some psychiatric populations has begun to show conclusive results. 
Meta-analyses of MDD studies typically suggest that LTL is decreased in diagnosed 
patients compared to controls, especially in those displaying chronic or severe 
symptoms.9,10 Findings in anxiety disorders are more mixed, but meta-analyses seem to 
agree that evidence supports significant LTL shortening, especially within more severe 
anxiety disorders.9,10 Though not entirely conclusive due to a small number of published 
studies and prevalence of confounding factors, existing evidence supports the shortening 
of LTL in PTSD patients.9,10 Recent meta-analyses report the overall findings on LTL in 
bipolar disorder to be inconclusive, perhaps due to a particularly significant confounding 
effect of psychotropic mediation in these patients.9,10 In conclusion, there is suggestive 
evidence that accelerated telomeric degeneration is implicated in many 
psychopathologies. The remainder of this discussion will examine the currently published 
data on LTL in psychosis patients, consider potential limitations and confounds to the 
concept of LTL as a reliable biomarker in this population, and suggest exciting future 
directions for this field of research. 
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SPECIFIC AIMS 
The specific aims of this thesis include: 
1) To conduct a comprehensive review of the literature in order to better understand 
the relationship of leukocyte telomere length and psychosis 
2) To determine of how reliably telomere degeneration in psychosis can be utilized 
to make predictions on disease chronicity, severity, and recurrence 
3) To address the need for investigation of leukocyte telomere shortening in 
prodromal and recent-onset patients, in order to determine whether the 
phenomenon could act as an early predictive biomarker  
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ACCELERATED AGING IN SCHIZOPHRENIA 
 
Accumulating evidence suggests that patients diagnosed with schizophrenia have lower 
life expectancies and more comorbid medical issues than other psychiatric patients.6 
While unhealthy lifestyle choices, substance abuse, and poor access to care have a 
significant impact on the mortality rate of this population, more findings are beginning to 
suggest that these factors do not fully account for the lowered life expectancy.6,18 The 
prevalence at which illnesses such as type 2 diabetes, cardiovascular disease, and other 
metabolic irregularities are observed in schizophrenia patients at abnormally young ages 
has frequently been attributed to side effects of antipsychotic medication.19 However, the 
relationship between schizophrenia and type 2 diabetes mellitus has been known since the 
19th century, long before the discovery of antipsychotic therapeutics.18 This has caused 
some investigators to suggest that early metabolic dysregulation in schizophrenia is 
independent of medication, implying instead that accelerated pathological aging plays a 
 
Figure 2 – Hypothesized Role 
of Accelerated Aging in 
Schizophrenia 
Proposed by Shivakumar et al. 
(2014)5 
• Depicted hypothesis lacks a 
clear starting point, as it is 
unclear whether accelerated 
aging first causes structural 
brain changes leading to 
schizophrenia (SZ) or 
whether the pathophysiology 
of SZ exacerbates cellular 
aging  
• Note also that no distinct 
causality is depicted between 
SZ and TL 
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role in psychosis.6,18,20,21 The constellation of issues such abnormal blood pressure, 
dyslipidemia, and increased adiposity that predispose comorbidities such cardiovascular 
disease and diabetes in schizophrenia patients are collectively referred to as the metabolic 
syndrome.20 Metabolic syndrome is a pro-inflammatory state that increases oxidative 
stress systemically, affecting roughly 32.5% of schizophrenia patients.22 Shivakumar et al 
(2014) uses this markedly early incidence of aging-related metabolic dysregulations in 
addition to novel neuroimaging findings, immunological studies, and LTL analyses to 
hypothesize a plausible connection between accelerated aging and schizophrenia5 [Figure 
2]. The review prescribes a central role in this hypothesized connection to vitamin D, the 
validity of which remains to be tested. Of greater interest is the idea that chronic 
inflammation, oxidative stress, and telomeric degeneration simultaneously impact 
pathophysiological aspects of schizophrenia and accelerated aging, as this avoids the 
unresolved question of whether pathological aging and the metabolic syndrome precede 
or result from psychosis. A growing body of literature is reporting an association between 
chronic inflammation, oxidative stress, and schizophrenia, thereby supporting the 
coincidence of accelerated aging and psychosis. For instance, a review article analyzing 
the role of neuroimmunological defects in schizophrenia found substantial evidence 
suggesting that an altered expression of immune system genes and the resultant 
imbalance of anti-inflammatory cytokines contribute to both structural and functional 
brain abnormalities in schizophrenia patients.23 Additionally, there have been studies 
finding positive therapeutic effects of anti-inflammatory agents on cognitive, negative, 
and even positive psychotic symptoms.24,25 Okusaga (2014) focuses on the potential role 
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of oxidative stress on pathological aging in schizophrenia.26 The study concludes that, 
due to common confounding factors of this population that feasibly could have an effect 
on oxidative stress (smoking, diet, antipsychotic medication), the currently available data 
precludes an unequivocal prescription of symptoms of premature aging to a 
schizophrenia diagnosis. However, Okusaga (2014) does attribute chronic inflammation 
to be in part responsible for the increased oxidative stress in schizophrenia, which would 
explain the prevalence of metabolic changes and premature aging-related pathologies in 
these patients. Lastly, there have been investigations showing significantly higher 
numbers of markers for irreversible protein oxidation in schizophrenia patients than 
healthy controls,26,27 as well as adjunctive antioxidant therapies reducing the symptoms of 
schizophrenia.26,28,29 Both of these findings once again suggest that the relationship 
between schizophrenia and its metabolic symptoms related to pathological aging is 
complex and cannot be accounted for solely by the side effects of antipsychotic 
medications.    
 
Recent investigations provide support for the theorized link between psychosis and 
pathological aging. Czepielewski et al (2017) evaluates the relationships between age, 
TL, biomarker CCL11, gray matter volume, and episodic memory performance in 48 
schizophrenia patients compared to 64 healthy controls.30 Previous findings of an 
increase in CCL11 in patients with chronic but not recent-onset schizophrenia imply that 
the pro-inflammatory chemokine acts as a biomarker for worsening, degenerative 
pathological aging.31 Czepielewski et al (2017) reports that, compared to 
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demographically similar controls, schizophrenia patients had worse memory 
performance, increased CCL11, reduced TL, and decreased total gray matter volume.30 
These parameters behaved, with the exception of gray matter volume, independently 
from participant age, implying that the worsened outcomes summarized above reflect not 
age itself, but the impact of disease-associated accelerated aging. The study’s major 
shortcomings were its cross-sectional design and small sample size. Future large scale 
longitudinal investigations are required in order to definitively ascertain the relationship 
between psychosis and accelerated aging.  
 
A study on cerebral white matter aging in schizophrenia and major depression, Kochunov 
et al (2013), reveals an interesting discordance between the two psychiatric disorders. As 
stated in the introduction, the current findings of studies in depressive disorders on LTL 
shortening suggest that advanced cellular aging is positively linked to depressive 
symptom severity and chronicity. However, Kochunov et al (2013) reports findings that 
only show significant accelerated cerebral white matter aging in schizophrenia, not Major 
Depressive Disorder (MDD).32 Additionally, white matter tracts that matured later in life 
showed heightened sensitivity to the effects of schizophrenia and were more susceptible 
to disorder-related accelerated degeneration. No such trend was observed in MDD. This 
implies a potential difference in the pathophysiology of the two psychiatric disorders and 
suggests that the relationship between psychosis and premature aging should be studied 
independently from the influence of results in other disorders. This trend of differentially 
accelerated cellular aging among psychiatric disorders is replicated by Koutsouleris et al 
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(2014). The study analyzes deviation from the trajectory of normal brain maturation, as 
measured by the difference between chronological and neuroanatomical age, in various 
psychiatric patient cohorts.33 The findings report the highest deviation to be in the 
schizophrenia patient group with smaller, yet still significant deviations seen in MDD and 
bipolar disorder patients. There is no significant association between abnormal trajectory 
of brain maturation and illness duration cited in any of the groups studied, contradicting 
the idea that accelerated aging manifests as a result of progressive neurodegeneration. 
This could simply be explained by the limitation of the study’s cross-sectional designs. 
The authors do however report a linear increase of deviation from normal trajectory 
starting from patients experiencing early, attenuated psychotic symptoms all the way to 
chronic schizophrenia patients. This suggests a possible correlation between severity of 
pathological aging and severity of psychotic symptoms. None of these findings were 
attributed to common confounds such psychotropic medications, alcohol, smoking, or 
socioeconomic status. 
 
Several studies have used this noteworthy incidence of accelerated aging-related 
symptoms to reframe schizophrenia as a somatic disorder. As previously alluded to, 
schizophrenia is associated with a striking increase in mortality.34 It is generally accepted 
that increased risk of suicide, poor health habits, and the metabolic side effects of 
antipsychotics play a significant role in this mortality rate.18,34 However, Kirkpatrick et al 
(2008) hypothesizes that the physiological abnormalities associated with schizophrenia 
themselves contribute to this increased mortality.18 This would implicate schizophrenia in 
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serious somatic health risks. Jeste et al (2011) rejects the idea of aging as a uniform 
process and cites a marked divergence in physical, cognitive, and psychosocial aging, 
especially in psychosis patients.35 Despite persistent, mild cognitive impairment starting 
in the premorbid period, the study cites a normal rate of cognitive aging in schizophrenia 
patients. Psychosocial functioning notably improves with age in the overall population 
according to this study. The only pathological increase was observed in physical aging. 
The authors therefore suggest that the targeted treatment of these biological symptoms 
could lead to improved long-term prognoses and would eliminate the conception of 
schizophrenia as a life sentence. Finally, a study by Papanastasiou et al (2011) 
reclassifies schizophrenia as a whole-body disorder caused by segmental progeria 
(degenerative aging), citing similar genetic and clinical similarities between 
schizophrenia and aging-related disorders as observed by the aforementioned studies.36 
The authors argue that the growing body of evidence in support of this reformulation 
shatters the prevailing mind/body dualism, encourages future investigations into somatic-
based therapies, and highlights the impact that definitive biomarkers can have on the 
more confident diagnosis of this complex disorder.  
 
In conclusion, psychosis and accelerated biological aging appear to be sufficiently linked 
to warrant research into reliable markers predictive of the two phenomena. As indicated 
in earlier sections, findings in related fields suggest that LTL and telomeric degeneration 
have the potential to serve as this type of marker.  
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LEUKOCYTE TELOMERE LENGTH IN SCHIZOPHRENIA 
 
Shorter LTL in Schizophrenia 
The majority of studies on LTL in schizophrenia report shortened telomeres in patients 
compared to healthy controls. Kao et al (2008) summarizes two study designs: one 
independent group analysis of schizophrenia patients, unaffected family members, and 
unrelated healthy controls, as well as an age-matched analysis of male schizophrenia 
patients and controls.37 Both analyses ultimately control for age and sex and report 
findings of significantly reduced LTL in the patient groups. The examination of family 
members in the first study aims to eliminate potential confounding genetic factors. Based 
on these findings, the authors estimate that the rate of telomeric degeneration is more 
than doubled upon the onset of schizophrenia. This estimation is most significantly 
limited by the cross-sectional nature of the study. A true determination of telomeric 
degeneration rate throughout the course of illness can only be attained through future 
longitudinal studies. Fernandez-Egea et al (2009) supports this trend with findings of 
decreased leukocyte telomere content and increased pulse pressure in patients with 
nonaffective psychosis.38 The authors use this measured decrease in LTL and the 
increased indices linked to accelerated aging, diabetes, and hypertension, to support a 
hypothesis of the concrete pathophysiological aspects of schizophrenia directly impacting 
an increased rate in mortality. Galletly et al (2017) replicates these exact findings of 
shortened LTL in schizophrenia patients as compared to healthy controls.39 Due to the 
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study’s recent date of publication, the authors are highly conscious of previous studies’ 
limitations and aim to control for as many potential confounds as possible. Patients and 
controls are therefore all male, aged-matched, fall into a narrow range of ages, and 
originate from the same geographic area. This study sets an important precedent for the 
exclusion of independent factors, however continues to leave room for future 
(longitudinal) investigations to determine whether the relationship holds over time. 
Czepielewski et al (2016) also reports shortened LTL in schizophrenia patients compared 
to controls, while adding a unique, noteworthy finding.40 It is the first study to show that 
unaffected siblings did not differ in telomere length from subjects with schizophrenia. 
This implies the possibility of an underlying, inheritable accelerated telomeric attrition 
endophenotype, which increases one’s risk of developing a psychotic disorder. Although 
these findings have yet to be replicated, the authors suggest that these results could open 
a venue for increased investigations into peripheral aging markers in at-risk populations. 
One should also note that the sample sizes employed in this study are small (36 
patients/36 siblings/ 47 controls), and that the authors did not address several common 
confounding factors. 
 
Of the numerous studies citing significantly shortened LTL in schizophrenia, a handful 
report additional findings on potential relationships between LTL and disease chronicity, 
symptom severity, or treatment route. Pawelczyk et al (2015), for instance, compares 
LTL in chronic and early schizophrenia cohorts in order to assess the relationship 
between telomere length and disease chronicity/severity.41 The results elucidate 
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significantly higher telomere erosion in chronic schizophrenia, symptom severity to be 
negatively associated with TL, as well as a significant correlation between LTL 
shortening and the number of psychotic episodes/hospitalizations. A regression analysis 
proposed that knowledge of the study group (chronic vs. early), age, sex, and number of 
episodes/hospitalizations allows one to significantly predict TL, with over 50% of 
variance explained by these factors alone. Important limitations of this study include the 
authors’ inability to control for certain residual confounding covariates (parental age, 
physical activity, systemic inflammation, obesity, and red meat consumption) as well as 
the fact that all participants were recruited upon hospitalization for psychotic 
exacerbation and may therefore not be representative of the general population of 
individuals with schizophrenia. Yu et al (2008) additionally sheds light on the impact of 
duration of illness and symptom severity on telomeric degeneration.42 The study 
separates participants with chronic schizophrenia into “good responders” and “poor 
responders” to treatment, based on their Global Assessment of Function score. It reports 
significantly shorter LTL within the “poor responder” group as compared to both “good 
responders” and healthy controls. The findings suggest that treatment-resistant patients 
with chronic schizophrenia have significantly shorter telomeres due to uncontrolled 
factors such as oxidative stress that also leads to ensuing cellular dysfunction. This 
relationship is still purely speculative, and the study’s results are limited by sample size 
and the potentially confounding covariates. However, Kota et al (2015) replicates similar 
findings.43 The study classified 35 subjects as remitted schizophrenia patients and 36 
subjects as unremitted, based off the Clinical Global Impression Severity scale. The 
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results reveal telomeric degeneration to be significantly higher in unremitted 
schizophrenia patients than in either controls or their remitted counterparts. Therefore, 
there have now been replicated reports of worsened LTL shortening in unremitted/poor 
responder patient cohorts. Future longitudinal studies would help determine whether 
remission potentially slows down the rate of telomeric degeneration, whether telomeric 
shortening is indicative of the likelihood of remission, or whether both TL shortening and 
poor response are driven by a third common factor. 
 
Reduced Telomerase Activity in Schizophrenia 
The group of researchers behind the Kao et al (2008) paper followed up on their initial 
findings with an analysis of telomerase activity in schizophrenia patients, unaffected 
family members, and unrelated healthy controls.44 In this follow-up paper, Porton et al 
(2008) demonstrate a nominally significant reduction in telomerase activity in 
schizophrenia patients as compared to unaffected individuals. Significant variation in 
lymphocyte telomerase levels within the diagnostic groups suggests that this enzymatic 
activity is subject to physiological fluctuations and does not follow the same typically 
clear neurodegenerative trends with age as LTL. Nonetheless, these findings imply that a 
reduction in telomerase activity plays a role in the process of accelerated cellular aging in 
schizophrenia, though it is not likely to be the main cause of LTL shortening. Rao et a 
(2015) supports this hypothesis in finding an association between several single-
nucleotide polymorphisms (SNPs) within the telomerase reverse transcriptase (TERT) 
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gene and paranoid schizophrenia.45 Their findings also report a significantly shorter mean 
LTL in paranoid schizophrenia cases compared to healthy controls. However, the two 
results were not significantly associated, implying that the schizophrenia-risk associated 
SNPs might have no direct effect on LTL. Though there is therefore some support for 
reduced telomerase activity in schizophrenia, the exact relationship remains inconclusive. 
 
Inconclusive Findings  
Several studies have null findings regarding LTL in schizophrenia. Mansour et al (2011) 
responds to prior reported findings of shortened LTL in schizophrenia patients by testing 
TL as a potential link between the disorder and consanguinity, a supposed risk factor for 
certain psychopathologies.46 The results are largely inconclusive and neither show an 
overall association between inbreeding and TL nor replicate shorter LTL in the 
schizophrenia group. Malaspina et al (2014) also did not observe a significant difference 
in LTL between patient and control groups, despite a higher incidence of smoking in the 
schizophrenia participants in their sample, which should be indicative of an increased 
oxidative stress and likelihood of telomeric degeneration.47 A follow-up study by the 
same research team, Malaspina et al (2016), analyzes the effect of paternal age on odor 
sensitivity in schizophrenia patients and healthy controls.48 The study measures LTL as a 
potential explanatory factor for the two variables in question, but is once again unable to 
report a significant difference in LTL between patients and controls. A prospective 
longitudinal study, Li et al (2015), analyzing the association of PBMC telomere length 
and mitochondrial DNA copy number with risperidone treatment in first-episode, 
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antipsychotic-naïve schizophrenia patients is similarly unable to report a significant 
difference in TL between patients and controls both at baseline and 8 weeks after initial 
medication administration.49 While a markedly lower mitochondrial DNA copy number, 
a related biomarker of cellular aging, is reported in schizophrenia patients compared to 
controls, the expected association between TL and mitochondrial DNA copy number was 
only observed in healthy controls. The authors address several factors that could have had 
a confounding effect on the TL findings, but also postulate that telomeric degeneration 
could simply be largely influenced by chronic levels of oxidative stress that are not yet 
seen in this cohort of patients with shorter durations of illness. Wolkowitz et al (2017) 
analyzes a relatively large sample (134 psychosis patients/123 healthy controls) and 
reports that gender, not the diagnosis, was the major factor involved in LTL shortening.50 
It is of the note that the study enrolled patients with schizophrenia and schizoaffective 
disorder diagnoses, in contrast to other studies that either focus exclusively on 
schizophrenia or exhibit less well-defined inclusion criteria. Despite the potential 
difference in incidence of depressive symptoms having a plausible influence on LTL, the 
publication cites no significant between-group differences for schizoaffective and 
schizophrenia patients. While the results fail to elucidate a significant difference in LTL 
between patients and controls overall, they do reveal shorter LTL in women with a 
psychotic disorder compared to female controls. In addition, men are shown to have 
shorter LTL than women at any given age, and LTL declines more rapidly in men. The 
authors use these findings to emphasize the importance of analyzing the effect of 
psychosis on LTL separately for each gender and go as far as to suggest that the 
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previously discussed inconclusive studies (Mansour et al, Malaspina et al, Li et al)46,48,49 
operated under the likely false assumption that the rate of decline in LTL is constant 
between the two genders. Lastly, Monroy-Jaramillo et al (2017)51 analyzes a relatively 
large sample of schizophrenia patients of Hispanic descent (170 patients/126 controls), 
but fails to find a significant correlation between LTL and the disease status.  
 
Longer LTL in Schizophrenia 
As of this date, only two studies have reported significant findings of longer LTL in 
schizophrenia patients as compared to healthy controls. Nieratschker et al (2013) sets out 
to replicate previously reported findings of shortened LTL in schizophrenia patients with 
a large sample analysis (539 patients/519 controls).52 However, the results reveal LTL to 
be significantly longer in the patient group than in the control group, before and after 
adjusting for incidence of smoking. Separate age-subgroup analyses suggest that these 
unusual findings are not attributable to mortality bias. Similarly, a significant reported 
correlation between age and LTL suggests that telomere length measurement and analysis 
methods were valid. This result is nonetheless unexpected even for the authors, who 
address possible confounding effects of advanced paternal age and psychotropic 
medications. Data on lifetime quantities of psychotropic medication or paternal age were 
not available, making it impossible to rule out these confounds. There is therefore a 
significant amount of uncertainty surrounding this well-powered analysis. This 
unexpected result of elongated LTL has been replicated in one additional, fairly recent 
study, Cui et al (2017).53 In this case, both early and chronic psychosis patients cohorts 
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exhibit significantly longer TL than healthy controls after controlling for a large subset of 
confounds. It is important to note that the study measures TL in only a subset of 
leukocytes, T lymphocytes, in order to attain more consistent results. While the authors 
portray this decision as a strength of the study, as it will hopefully usher in a future 
standard of more reliable TL measurements, one should also consider that this difference 
in measurement techniques could render the findings of this particular study slightly less 
comparable to previous results. This possibility becomes increasingly important upon the 
realization that the results fail to replicate significant correlations between TL and 
chlorpromazine-equivalent antipsychotic dosages, duration of illness, or even age. The 
authors address the lack of correlation between TL and age by citing a relatively young 
average sample age in addition to reports from prior studies failing to find a correlation. 
With the inverse relationship between age and TL becoming increasingly established, 
however, one is left to inquire if the results of Cui et al (2017) are not more plausibly 
influenced by independent factors. 
 
Meta-Analyses 
Two meta-analyses have been published, to date, analyzing the overarching association 
between schizophrenia and LTL reported in case-control studies. Studies referenced 
above that strictly focus on telomerase activity or did not employ a healthy control 
comparison group are therefore not included in these analyses. The earlier analysis, Polho 
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et al (2015), is limited to the seven studies available at the time [Table 1] which utilize 
diverse methodologies and do not contain perfectly comparable samples.54 The initial 
results do not reveal a significant difference in LTL between patient and control groups 
(p=0.074). Crossvalidation shows that Nieratschker et al (2013),52 the only study at the 
time reporting longer LTL in patients, is responsible for the majority of heterogeneity of 
the model. Exclusion of this study results in a significant model in which LTL is 
shortened in schizophrenia patients compared to controls (p = 0.027). Despite a lack of 
statistically significant findings, the study cites sufficient suggestive evidence in support 
of a hypothesis of diminished telomere length in schizophrenia. There are serious 
Table 1: Meta-Analysis 1 – Leukocyte Telomere Length in Case-Controlled 
Schizophrenia Studies 
Seven case-control studies were included in this analysis. This table summarizes 
measurement methods, sample sizes, mean LTL, and study conclusions.54 
 
Adapted from Polho et al. (2015) 
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limitations to this hypothesis. Firstly, while the exclusion of Nieratschker et al 
(2013)52does produce a significant trend, this particular investigation features the largest 
sample size among all of the studies analyzed. The analysis also pools medicated and 
antipsychotic-naïve patients as well as responders and non-responders to treatment into a 
single analysis cohort, even though these subgroups have displayed alternate associations 
to LTL in individual analyses. Lastly, this model of pooled studies is unable to account 
for several potentially confounding variables, such as oxidative state, medical 
comorbidities, smoking habits, and paternal age. In a letter to the editors of Schizophrenia 
Research, Pao-Yen Lin argues that Polho et al (2015) neglected valuable information in 
their publication due to an insufficiency in meta-analytic methods employed.55 Lin’s 
analysis methods applied to the same pool of seven studies yield a marginal decrease in 
TL in the patient group (p = 0.051) and notably attribute the pool’s heterogeneity to the 
fact that poor-responders and antipsychotic-naïve patients displayed significant LTL 
reduction, whereas other medicated patients did not differ significantly from controls. 
This implies that disease status (i.e. severity, resistance to pharmacotherapy) rather than a 
schizophrenia diagnosis in general may be associated to leukocyte telomere shortening. 
More recently, Rao et al (2016) aimed to reconcile the controversy around telomere 
length in schizophrenia by first measuring LTL in an independent sample of patients and 
controls, and then incorporating their results into a comprehensive meta-analysis.56 The 
authors’ own sample displays a significant overall decrease in LTL in individuals with 
schizophrenia compared to healthy controls. Subgroup analyses reveal that paranoid 
schizophrenia is associated with LTL, whereas no significant difference is observed 
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between nonparanoid schizophrenia and controls. In their meta-analysis, 11 studies 
encompassing 1243 patients and 1274 healthy controls were pooled into a final analysis 
model [Figure 3]. 
 
 
Figure 3 – Meta-Analysis Forest Plot: LTL in Patients vs. Controls 
A list of studies included in the meta-analysis, Rao et al (2016). Standard Mean 
Difference (SMD) scores of LTL measurements are displayed. The dashed red line 
signifies the SMD of the of the overall analysis pool. A significant overall decrease in 
LTL is observed in schizophrenia patients.   
 
Figure adapted from Rao et al. (2016) 56 
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Despite heterogeneity within the pooled sample, a significant decrease in LTL is reported 
overall in schizophrenia patients compared to controls (p = 0.039). In an attempt to 
explain the observed heterogeneity, subgroup analyses were conducted and revealed a 
marginal decrease (p = 0.055) in LTL in medicated patients as compared to anti-
psychotic-naïve patients and controls [Figure 4]. 
 
Figure 4 – Subgroup Analysis Forest Plot:  
LTL in Medicated/Antipsychotic-Naïve Patients vs. Controls 
The dashed red line signifies the SMD of the of the overall analysis pool. A marginal 
decrease in LTL is observed in medicated patients.  No significant difference between 
antipsychotic-naïve individuals and control group. 
 
Figure adapted from Rao et al. (2016) 56 
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Similarly, patients with a reported poor response to antipsychotic treatment displayed a 
marginal decrease (p = 0.078) in LTL compared to the remaining subjects within the 
analysis [Figure 5]. 
 
 
 
 
Figure 5 – Subgroup Analysis Forest Plot:  
LTL in Good Responder/Poor Responder Patients vs. Controls 
The dashed red line signifies the SMD of the of the overall analysis pool. A marginal 
decrease in LTL is observed in poor responder patients.  No significant difference 
between good responders and control group. 
 
Figure adapted from Rao et al. (2016) 56 
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Any study published after 01/01/2016 postdate this analysis. Of the studies outlined 
above, five were published past this date. Czepielewski et al (2016) and Galletly et al 
(2017) report shorter LTL in schizophrenia patients compared to controls; Cui et al 
(2017) reports longer LTL in patients; and Wolkowitz et al (2017) and Monroy-Jaramillo 
et al (2017) find no difference.40,39,53,50,51 This broad range of results does not suggest any 
directionality and therefore highlights the importance of additional future investigations 
and meta-analyses.  
 
In conclusion, the most comprehensive meta-analysis to date reports a significant 
incidence of leukocyte telomeric degeneration in patients with schizophrenia, supporting 
the hypothesis that pathological accelerated aging is significantly associated with 
psychosis.  
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LEUKOCYTE TELOMERE LENGTH IN EARLY PSYCHOSIS 
There appears to be an association between LTL shortening and schizophrenia. However, 
in order to determine whether LTL could potentially serve as a biomarker for the onset or 
worsening of psychosis, the relationship between LTL and duration of illness has to be 
studied. Schizophrenia is not a static disorder, but has rather been categorized into 
progressive clinical stages.57 These range from attenuated, prodromal psychotic 
symptoms all the way to chronic, debilitating conditions. It is well established that the 
improvement observed in patients with chronic schizophrenia is lower than that in 
patients with a shorter duration of symptoms, suggesting a potential link between disease 
chronicity and severity.41 Duration of illness is therefore an important variable in this 
patient population, and yet it is often overlooked when grouping patients into broad 
diagnostic groups. Only one study reviewed above, Pawelczyk et al (2015), currently 
investigates a potential difference in LTL between early and chronic schizophrenia 
patients.41 Though its findings strongly suggest an association between duration of 
recurrent or heightened psychotic symptoms and leukocyte telomere degeneration, these 
results have yet to be replicated. Only three publications currently describe case-control 
studies in which LTL is analyzed in first-episode/recent-onset schizophrenia patients. 
Fernandez-Egea et al (2009) reports significant LTL shortening in this specific 
subpopulation, whereas Cui et al (2017) reports a significant increase in LTL, and Li et al 
(2015) finds no conclusive association whatsoever.38,53,49 There is therefore an 
unequivocal need for further investigation into whether LTL is linked to some underlying 
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neurodegenerative pathophysiology of schizophrenia or is significantly shortened even 
within the early stages of the disorder. 
 
An important aspect of early psychosis research is the ultra-high risk (UHR) concept, 
based on the observation that schizophrenia is usually characterized by a prodromal 
period that precedes the onset of full-blown psychotic symptoms.58 Subthreshold positive 
symptoms, a decline in functioning, and a family history of psychotic disorders are the 
most common criteria of the UHR label. Identification of the prodrome and early 
intervention are thought to be the key to preventing or at least improving the prognosis of 
a schizophrenia diagnosis. The early identification of psychosis is complicated by the fact 
that not every individual meeting UHR criteria will transition to develop a psychotic 
disorder and that the attenuated psychosis-like experiences exhibited by this population 
are often merely clinical noise, unrelated to the risk of developing schizophrenia. The 
identification of a definitive biomarker such as LTL within UHR individuals would 
therefore greatly advance the detection and treatment of psychosis. As alluded to earlier, 
Koutsouleris et al (2014) notes a significant deviation from the trajectory of normal brain 
maturation in schizophrenia patients.33 Though the deviation was the most pronounced in 
schizophrenia, the authors replicated these findings in MDD, borderline personality 
disorder, and UHR individuals. Additionally, this deviation showed a linear increase from 
individuals having recently met UHR criteria to recurrently ill, chronic schizophrenia 
patients. Though unique and unreplicated, this study therefore implies that pathological 
accelerated aging can feasibly be detected in individuals at-risk for psychosis and 
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progressively worsens as symptoms progress. This emphasizes the need for research in 
telomeric degeneration within this population. However, only one study to date has 
analyzed TL attrition in UHR subjects.59 Maurya et al (2017) provides significant 
evidence that shorter LTL could be associated with UHR status compared to healthy 
controls. However, the study’s sample is relatively small (22 UHR subjects, 88 healthy 
controls), and no other measures of pathological aging (oxidative stress, immune-
inflammatory agents) were collected in support of these findings. 
   
 
In conclusion, while there is emerging conclusive evidence of LTL shortening in the 
early stages of psychosis, future investigations are needed to elucidate the relationship 
between telomeric degeneration and the progression of schizophrenia. In order to truly 
assess the potential of LTL as a predictive biomarker for psychosis, longitudinal studies 
following individuals from the prodrome into subsequent stages of full-scale 
schizophrenia are needed.       
Figure 6 – Decreased LTL in UHR Patients 
compared to Healthy Controls 
Data shows the predicted values for T/S 
(telomere/single copy gene) ratio after 
controlling for age, sex, ethnicity and years of 
education. 
Figure adapted from Maurya et al. (2017)59 
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CONFOUNDING FACTORS 
With the growingly accepted association between schizophrenia and pathological aging, 
additional studies are driven to investigate the potential link between LTL attrition and 
psychosis. The currently most comprehensive meta-analytical data is in support of this 
link, and yet results in this field of study have been relatively incongruous. A growing 
body of studies is failing to replicate findings of a significant correlation, and two 
publications are now in support of longer LTL in schizophrenia patients compared to 
healthy controls. While this apparent disagreement has encouraged future clarifying 
investigations, a number of potentially confounding covariates need to be eliminated in 
order to elucidate the true relationship between telomere length and schizophrenia.  
1. Age 
The negative correlation between LTL and age is well established.9 Despite this inherent 
difficulty in comparing telomere length in two non-age matched groups, not all 
investigations are able to perfectly control for age differences between their patients in 
controls. Rao et al (2016), for instance, in conducting a meta-analysis that pools together 
vastly heterogeneous patient and control samples, is unable to control for the resulting 
discordance in mean age between the two pooled groups.56 Future case control studies 
investigating LTL as a potential marker for pathological aging in schizophrenia should 
ensure to control for age, in order to eliminate any potential confounding effect of normal 
age-associated telomeric attrition. 
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2. Study Design 
Age can continue to be an issue even in a perfectly age-matched study, due to the fact 
that in controlling for age, one is typically forced to operate under the assumption that all 
trajectories of LTL with age parallel each other.50 Should this assumption be false and 
LTL trajectories were actually to vary significantly with age in healthy individuals, there 
would be a considerable, inherent flaw in cross-sectional study designs. It is difficult to 
identify pathological LTL shortening when no standard of normal age-related LTL 
shortening exists. This highlights the importance of future longitudinal studies within this 
field. With large enough sample sizes, cross-sectional studies are able to reveal 
significant standardized mean differences. In order to determine whether at one point 
LTL predicts subsequent development or worsening of disease, longitudinal 
investigations are needed. All studies discussed above utilized a cross-sectional design. 
Many therefore cite this as a major limitation to their findings, as they are unable to 
account for any subject-level covariates or to postulate anything beyond a significant 
correlation between schizophrenia and LTL degeneration. 
  
Other study design-related, potentially confounding covariates include DNA extraction 
and telomere length analysis methods. While these factors may theoretically be the most 
feasibly controlled, they can produce a significant amount of variability from study to 
study. For instance, longer telomeres have been observed in DNA that is extracted 
automatically compared to manually extracted samples.52 Analysis methods surrounding 
LTL data have also been suggested to have a substantial impact on a study’s end result.55 
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While often negligible, these potentially confounding factors should especially be 
considered when performing cross-study analyses.         
 
3. Sex 
Aside from age, sex is the most widely acknowledged potential confound in LTL 
analyses. Studies have shown greater telomere lengths in women compared to age-
matched men, suggesting that for a given chronological age, biological aging of men is 
more advanced than that women.9,60 Some studies have expanded on this observation in 
order to investigate whether these sex-related differences in TL are present at birth or 
develop over the course of the lifespan. Typical findings report no evidence for the effect 
of sex on telomere length at birth, rather suggesting that the longer telomeres in women 
than men arise from a slower rate of telomeric attrition in women.61 The outlined delay in 
telomere shortening interestingly mirrors a later average age of disease onset in female 
schizophrenia patients.62 This apparent sex-dependent parallel could be considered to 
support a hypothesized association between psychosis and telomeric degeneration. As 
described above, the case control study, Wolkowitz et al (2017), was unable to find a 
general association between LTL and schizophrenia, attributing LTL shortening to 
differences in gender instead.50 Interestingly, the study does find significantly shorter 
LTL in women with schizophrenia compared to female controls. This highlights the 
potential confounding effect of sex within this population and emphasizes the need for 
future studies to control for sex-related differences. 
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4. Other Subject-Level Variables 
In addition to age and sex, there are several other subject-level variables that could play a 
potentially confounding role in the assessment of LTL in schizophrenia patients. Healthy 
life style factors, such as diet and exercise, have been implicated.63 High body mass 
index, circulating glucose levels, and abdominal fat are associated with shortened 
telomeres, whereas intake of antioxidants, vitamins, and less processed meat are linked to 
longer telomeres.14,64 Numerous studies have studies have found associations between 
moderate to severe physical exercise and longer LTL.7 Chronic poor sleep quality has 
also been found to be predictive of shortened LTL in certain subpopulations.7,14 Small but 
significant associations between certain aspects of socioeconomic status, particularly 
educational attainment, and LTL have also been reported.7 The significance of these 
lifestyle factors on LTL is still largely unknown. The high prevalence of these factors in 
schizophrenia patients, however, suggests that they should receive consideration 
nonetheless.  
 
5. Substance Use and Tobacco 
In addition to an increased prevalence of unhealthy behavior, individuals with 
schizophrenia are at increased risk for developing substance abuse disorders.65 This 
proposes additional potential confounding effects on telomere length in this patient 
population. For instance, alcohol abuse has been found to lead to earlier onset of aging-
related diseases, and one study reports TL to be nearly halved in alcohol abusers 
compared to controls.66 There seems to be a strong negative correlation between TL and 
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the number of drink units consumed per day. Similarly, studies report significantly 
shorter LTL in drug abusers than healthy controls, suggesting an association between 
LTL attrition and drug addiction.67 Given the known oxidative damage caused by 
smoking, it is often assumed that tobacco consumption should also be associated with 
LTL degeneration.14 Published results are however largely contradictory, and a recent, 
large-scale (n = 4,576) 10-year-follow-up study reports no significant correlation between 
LTL and tobacco consumption, body weight, physical activity, or alcohol consumption.68 
This development puts into questions the associations between LTL and lifestyle factors 
reported by several cross-sectional studies. However, until a clear association is either 
established or disproven, future investigations should continue to control for these 
potentially confounding covariates.    
  
6. Genetics & Paternal Age 
LTL at birth has been found to be a major determinant throughout the lifespan.69 
Telomere length is therefore in part genetically programmed, and according to a major 
meta-analysis, TL heritability is estimated to be approximately 70%.9,70  The confounding 
effect of inherited differences between individuals is likely the hardest to control for in 
any study. However, as patient genotyping becomes less costly and more accessible in 
future years, investigators should make an effort to assess the potential impact of 
inherited polymorphisms on LTL.  
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Another inheritable determinant of LTL has been shown to be advanced paternal age at 
the time of conception.69,71 Various studies have illustrated that LTL is longer on average 
in offspring of older fathers.69 The root causes of this effect are still unknown. 
Interestingly, it has been observed that TL is longer in the sperm of older as opposed to 
younger men. This observation is contradictory to the normal age-dependent telomere 
shortening in proliferative somatic cells and may contribute to the advanced paternal age 
effect on offspring LTL. Given the widespread awareness of increased risk of genetic 
abnormalities and de novo mutations caused by advanced parental age, the idea that 
advanced paternal age may actually lengthen offspring LTL, thereby providing a 
plausible protective effect against aging-related disorders, has largely been considered to 
be enigmatic.71 Due to the possibility of advanced paternal age attenuating measurements 
of telomeric degeneration in schizophrenia patients, this phenomenon plays an important 
potential confounding effect on the studies analyzed in this discussion. The authors of 
Nieratschker et al (2013) acknowledge this in discussing the plausibility of their findings 
of increased LTL in schizophrenia patients to be attributed to advanced paternal age, not 
the disorder itself.52 Unfortunately, data on paternal age was unavailable to them and they 
could not test this claim. 
 
Interestingly, advanced paternal age is not just associated with longer LTL in offspring, it 
has also been implicated in raising the risk of schizophrenia.72,73 This finding is typically 
explained by the observation that advanced paternal age is strongly associated with an 
increase in de novo point mutations.72,74 These point mutations may, in part, contribute to 
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the etiology of schizophrenia. This increased risk of schizophrenia has been more 
strongly reported in male than female subjects. Similarly, Malaspina et al (2014) cites 
longer LTL in its male schizophrenia patients with older fathers, as opposed to shortened 
LTL in female counterparts.47 This has given rise to the hypothesis that advanced paternal 
age induces a unique phenotype of schizophrenia that coincidentally is associated with 
longer LTL. This theoretical unique phenotype is apparently more common in men. In a 
letter to the editors of Schizophrenia Research, the research team behind Malaspina et al 
(2014) responds to the unexpected findings of Nieratschker et al (2013) by analyzing 
their own outliers in order to identify demographic, cognitive, and symptom profiles 
associated with elongated leukocyte telomere length (eLTL) in schizophrenia patients.75 
This small pilot cohort of outliers reveals the same gender-specific trends on LTL 
observed by the effect of advanced paternal age, implying that the LTL observed in this 
sample is a unique phenotype associated with specific risk factors of psychosis and not to 
be generally associated with a schizophrenia diagnosis. Reports of either general or 
gender-specific LTL elongating effects of advanced paternal aging therefore reveal 
another important potential confounding effect, one that has typically not been controlled 
for in past studies.  
 
7. Comorbid Medical Conditions     
As alluded to earlier, roughly a third of schizophrenia patients are afflicted with 
metabolic syndrome.22 Rates of metabolic syndrome vary broadly among the general 
population due to genetic and geographical differences. However, schizophrenia patients 
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are considered to be at high risk compared to the general population, even after 
controlling for these variables. Notably, the syndrome remains prevalent in over 20% of 
non-medicated patients, illustrating that these systemic pathologies are not merely the 
side effect of antipsychotic therapeutics. Rather these symptoms reflect serious 
comorbidities that decrease an individual’s life expectancy and have even been found to 
negatively impact clinical wellbeing.24,26 Some of the common disorders grouped under 
this syndrome, such as type 2 diabetes mellitus and cardiovascular disease, can be 
classified as chronic inflammatory disorders and therefore enact a potentially 
confounding effect on telomeric attrition in these patients.14 The idea that comorbid 
medical illnesses may somehow be linked to telomeric degeneration and pathological 
aging is supported by the observation of greater incidences of metabolic syndrome in 
chronic schizophrenia in comparison to first-episode schizophrenia. Additionally, one 
should take into account a potential mortality bias, as subjects with the most severe 
medical conditions (and most severe cellular aging) are likely to die at a younger age and 
therefore become excluded from analyses, skewing the results. Despite these varied, 
Table 2: Major Features of 
Metabolic Syndrome 
 
Adapted from Mitchell et al. 
(2013)22 
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related potential confounding factors, medical comorbidities have not consistently been 
controlled for in past studies, especially within control groups.  
 
8. Comorbid Psychiatric Conditions 
The significant prevalence of accelerated LTL degeneration in nearly every major 
psychiatric disorder has been discussed above. Perhaps most important in its potentially 
confounding role on LTL studies in schizophrenia is depression.9 LTL shortening has 
been found to be significantly associated with MDD in case-control trials, and there have 
even been findings of significant links between LTL attrition and depressive symptom 
severity or chronicity.9,10 The coincidence of psychotic and depressive symptoms is 
incredibly high.76 The idea of parsing out any potential effect on LTL exerted by 
symptoms of depression within patients with psychotic disorders therefore seems nearly 
impossible. With several publications citing a unique model of pathological aging in 
schizophrenia, investigators can be reassured that the observed associations are not 
entirely influenced by comorbid mood diagnoses or depressive symptoms.32,33 Ratings on 
the severity of depressive symptoms should however be collected in future studies in an 
attempt to control for this potentially confounding effect.  
 
9. Chronic Stress & History of Trauma 
In an attempt to explore alternative mechanisms of telomeric attrition, Lindqvist et al 
(2015) summarizes several studies on the effect of stress hormones (cortisol and 
catecholamines) on LTL shortening. While there is no report of a clear link between LTL 
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and resting cortisol levels, there are somewhat consistent findings of an inverse 
relationship between LTL and cortisol release in response to psychological stressors.9 It 
is therefore easy to see why psychological stress and trauma could have a confounding 
effect on any observed increase in telomere degeneration within psychiatric patient 
populations. This effect would be especially pronounced in schizophrenia, due a high 
incidence of stress and trauma in these patients. Many large-scale population-based 
studies provide persuasive evidence of a dose-response association between childhood 
trauma and psychosis that is indicative of a causal relationship.77 Similarly, 80% of UHR 
youth endorse a lifetime history of childhood trauma or victimization, features that have 
been shown to be highly predictive of psychosis onset.78 It appears that these early 
incidences of psychological trauma set individuals up for vulnerability to stress-related 
psychiatric conditions and telomeric degeneration.63  
 
The effect of psychological stressors on LTL has been outlined in numerous publications. 
Epel et al (2004) reports that women with the highest levels of perceived stress have 
telomeres shorter on average by the equivalent of at least one decade of additional aging 
compared to low stress women.79 Price et al (2013) supports this proposed relationship 
with findings of an association between shorter LTL and sustained adulthood 
psychosocial stress of various types.80 The review also suggests an emerging trend of a 
dose-dependent relationship between early-life stress or adverse life events and 
pathological telomere degeneration observed in adulthood. This trend has been replicated 
in MDD and anxiety disorder patient populations, suggesting a plausible effect in 
		
 
41 
schizophrenia as well.81,82 Findings by Deng et al (2016) of decreased telomerase activity 
as a result of chronic stress are in agreement with the previous trends discussed.83 
 
Some studies are attributing a greater impact of early-childhood trauma on telomere 
attrition than just heightened susceptibility to stress-related pathologies. Tyrka et al 
(2010), for instance, reports that participants with a history of maltreatment had 
significantly shorter LTL than those who did not.84 Subscale analyses show both physical 
and emotional neglect to be linked to TL. The findings of Kiecolt-Glaser et al (2011) 
show multiple childhood adversities to be related to both heightened inflammatory 
cytokines and telomeric shortening.85 This implies a direct link between childhood 
adversity and pathological aging. In conclusion, the elevated prevalence of chronic stress 
and childhood trauma in this patient population, in addition to the strong causative 
implications of stress and trauma on telomeric degeneration amount to yet another 
important confounding covariate [Figure 7]. Ratings of childhood adversity and history of 
stressful life events should be collected in future studies in order to control for this effect. 
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Figure 7 – The Cycle of Trauma and Psychotic-Like Experiences 
A large body of evidence supports a causal relationship between trauma and 
psychosis. This figure expands on this by elucidating how a trauma-induced altered 
developmental trajectory can lead to psychotic-like experiences. 
Trauma also plays an important, potentially causative role in heightened telomeric 
degeneration. It remains to be determined if advanced LTL attrition and psychosis are 
independent comorbidities or if telomeric aging is a part of the depicted “altered 
developmental trajectory.” 
 
Figure adapted from Mayo et al. (2017)78 
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10. Psychotropic Medication            
The most common association between antipsychotic medication and symptoms of 
accelerated aging in schizophrenia is the knowledge that many therapeutics cause serious 
metabolic side effects.19 This discussion has presented multiple lines of evidence in 
support of metabolic syndrome being linked to pathological aging and telomeric 
degeneration, thus not solely being the result of medication side effects. However, the 
fact that antipsychotic medication does produce some of these seemingly aging-related 
metabolic symptoms implies that medication could have a confounding effect on 
measures of accelerated aging, including LTL, in schizophrenia patients. For instance, 
one study that failed to find a conclusive relationship between LTL and schizophrenia, 
Monroy-Jaramillo et al (2017), did however reveal significant telomere erosion in a 
group of subjects taking the atypical antipsychotic olanzapine, known for its high risk of 
causing metabolic issues.51 These findings suggest certain antipsychotic medication may 
have a modulating effect on LTL in schizophrenia patients. Since the patients taking 
olanzapine were not any more overweight and did not yet display advanced metabolic 
symptoms, it is unclear whether the observed decrease in TL is a result of metabolic 
disturbances caused by the medication or whether it is simply an independent covariate. 
Medication-induced telomere shortening is therefore plausible, but needs further 
investigation. 
 
 A more heavily studied inquiry is whether psychotropic medication has a protective 
effect against DNA damage and could therefore be attenuating measurements of LTL 
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attrition. One review reports that most currently used antidepressants are able to prevent 
or reverse neurotoxin-induced DNA damage, which suggests that this effect plays an 
important role in the relief of depressive symptoms.17 Savolainen et al (2012) expands on 
this by testing the effect of antidepressants and psychotropic medication on LTL in a 
large cohort of hospitalized patients.86 Patients hospitalized for psychiatric reasons who 
were taking either class of medications displayed significantly longer LTL than patients 
without a history of mental disorders. Psychiatric patients not taking antidepressant or 
psychotropic medications did not differ significantly in telomere length with the control 
group. Based on these results alone, TL seems to be exclusively associated with 
medication status, not any particular diagnosis. Nieratschker et al (2013) references this 
study in attempting to explain its unexpected findings of elongated LTL in schizophrenia 
patients, entertaining the idea that LTL is more associated with medications than 
pathology in this patient population as well.52 Martinsson et al (2013) reports similar 
findings in bipolar disorder, with long-term lithium treatment being strongly associated 
with longer LTL.87 These results have important implications in the study of LTL in 
schizophrenia, as adjunctive treatment with lithium is not uncommon this patient 
population.88 Interestingly, longer telomeres were also linked to the therapeutic efficacy 
of the drug. The better the response to lithium, the longer LTL was exhibited by 
individual patients. The authors hypothesize that the induction of telomerase is involved 
in lithium responsiveness, a concept that is replicated and expanded upon by Bersani et al 
(2015). This review raises the possibility that telomerase and other targets modulated by 
psychotropic medication mutually interact with and influence each other in order to bring 
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about the therapeutic effect in the treatment of all psychiatric disorders89 [Figure 7]. In 
ascribing such as ubiquitous role to telomerase, the authors emphasize the importance of 
the study of telomere biology in psychiatry.  
 
 
 
Figure 8 – Impact of Antipsychotics on Telomerase Activity 
Interaction of typical and atypical antipsychotics with D2 and D2/5HT2A receptors 
respectively enhances the inhibition of the AKT1/GSK3B pathway. This is 
hypothesized to lead to increased telomerase activity and consequent telomere 
elongation.54 
 
Adapted from Polho et al (2015) 
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The potential confounding role of psychotropic medication in modifying LTL in 
psychosis patients is substantial, but has not always been feasible to control in previous 
studies. It is unclear how much exposure to medication is required for a significant effect 
to take place, as Li et al (2015) did not find a measurable effect of risperidone treatment 
after 8 weeks.49 Longer periods of time may be required in order for an measureable 
effect to take place. Future studies should control for medication nonetheless.  
            
  
Not a single study discussed above was able to control for all of these vast potentially 
confounding covariates. Given the overall contradictory nature of the currently available 
data, one can plausibly assume that outside confounding factors were at play. Future 
studies should employ a longitudinal study design and monitor as many of these factors 
as possible in order to arrive at a more conclusive relationship between LTL and 
psychosis.    
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FUTURE DIRECTIONS 
The current state of the literature strongly suggests a significant relationship between 
schizophrenia and pathological accelerated aging. Cumulative evidence for increased 
incidence of inflammatory states, oxidative stress, and telomeric degeneration in 
psychosis patients compared to healthy controls collectively supports this relationship. 
However, current findings are limited to associations and plausible connections; neither 
causality nor chronicity has been established for any of these features observed in 
accordance with psychosis. The first major question that remains to be answered is 
whether some unexplored aspect of schizophrenia causes an acceleration in cellular aging 
or whether underlying phenomena, such as inflammation and oxidative stress, predispose 
individuals to both conditions.6 The answer may not even be mutually exclusive. 
Knowledge of the causality of this relationship could potentially revolutionize the field of 
psychopharmacology. It would either encourage closer monitoring and treating of aging-
related metabolic dysregulation in schizophrenia patients or conventionalize the treatment 
of early psychotic symptoms with adjunctive anti-inflammatory and antioxidant 
medications. A second important remaining inquiry is whether accelerated telomeric 
attrition is a feature of disease duration and/or severity or whether telomere shortening 
antedates the onset of psychosis and could therefore act as a viable predictive biomarker.9 
One study has cited significantly greater LTL degeneration in chronic schizophrenia 
patients compared to early cases, and another found a linear trend of neuroanatomical 
degenerative aging starting in prodromal patients and ending in chronically ill 
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individuals.41,33 These results do support a relationship between LTL and disease 
duration/severity, however require further replication.  
 
Despite the lack of a conclusive causal relationship, the large variety of factors linking 
schizophrenia and accelerated telomeric degeneration implies that their relationship is 
more than just a biologically unrelated correlation. A more likely explanation for their 
coincidence is that an early neurodevelopmental insult predisposes an indiscriminate 
subset of psychosis patients to augmented telomeric attrition. Such insults could include a 
genetic defect, early exposure to psychological stress and trauma, or a combination of 
factors. These proposed neurodevelopmental insults would likely not be unique to 
schizophrenia, as studies in most psychiatric disorders have yielded significant 
correlations with telomere shortening. However, some investigations indicate that 
pathological aging in schizophrenia could be differentially accelerated.32,33 This 
observation suggests that independent factors that are commonly associated with 
schizophrenia, such as chronic stress, antipsychotic medication, substance/tobacco use, 
and metabolic comorbidities could be amplifying the hypothesized predisposed telomeric 
degeneration. Seeing as these factors vary in individual patients, one can extrapolate a 
plausible explanation for the significant variation in LTL observed within the published 
literature. Ultimately, increased telomeric attrition could plausibly produce chronic 
inflammatory states and oxidative stress within schizophrenia patients, which would in 
turn contribute to aging-related symptoms and potential structural brain changes. The 
model outlined above is purely speculative, and future investigation is required in order 
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to gain a definitive understanding of the relationship between LTL and schizophrenia. 
Though dysfunctional telomere biology is not unique to psychosis, the possibility that 
telomeric degeneration affects disease outcome and could be differentially related to 
schizophrenia warrants investigation.              
 
There simply is not enough published data on recent-onset or UHR patients to make 
inferences about the potential ability of LTL to serve as a predictive biomarker. Current 
trends are promising as it appears that LTL degeneration, even if less severe than in 
chronic schizophrenia, is significantly measureable in early psychosis cases. Early 
detection and intervention are so crucial in the improvement of prognoses in psychosis 
cases that future investigations into the feasibility of LTL as a diagnostic biomarker are 
worthwhile. Longitudinal studies that control for age, sex, family history, substance use, 
and comorbid medical conditions will be instrumental in elucidating a definitive 
relationship between LTL and the course of psychotic disorders. Some studies should 
additionally focus on antipsychotic-naïve subjects, individuals with no significant history 
of trauma or stressful life events, and patients without depressive symptoms.  
 
With telomeric degeneration becoming implicated in a growing number of disorders and 
medical fields, another important future direction for research in general is determining 
how reversible this deterioration is. Several psychological and behavioral intervention 
studies in non-psychiatric populations have found a positive effect of intensive lifestyle 
modification, healthier eating habits, and meditative stress reduction on PBMC basal 
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telomerase activity and LTL.9,63 Especially physical exercise has been receiving a lot of 
attention for its putative therapeutic effect on telomere length. In a mouse model of 
schizophrenia, physical exercise was shown to increase adult neurogenesis and 
telomerase activity in addition to improving behavioral deficits.90 This result has been 
replicated to an extent in human studies, as noted by a review summarizing the 
alleviation of health deficits, symptoms, and biomarkers in schizophrenia spectrum 
disorders by physical exercise.91 Not as much effort has been devoted to finding 
pharmacological reversal methods of telomere degeneration. Approaches to reactivate 
telomerase by chemical means in various patient populations have been successful; 
however, seeing as increased uncontrolled telomerase activity is known to be 
carcinogenic, these have not been the most popular treatment route.14 With an increasing 
number of psychotropic medications displaying the potential of lengthening telomeres, 
the reversal of telomere attrition in psychiatric populations seems promising. Studies 
have shown that finite periods of TL lengthening have the potential to slow down or alter 
LTL degeneration trajectories.92 With further investigations, the reversal of aberrant 
telomere shortening could become a feasible treatment route for patients with psychotic 
disorders and provide promising impacts on individual prognoses.  
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